Fig. 4: Polygenic risk for hypothyroidism is associated with lower risk of death in European ancestry TNBC patients treated with atezolizumab and nab-paclitaxel. | Nature Communications

Fig. 4: Polygenic risk for hypothyroidism is associated with lower risk of death in European ancestry TNBC patients treated with atezolizumab and nab-paclitaxel.

From: Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade

Fig. 4

Kaplan–Meier (KM) plot for OS for triple-negative breast cancer (TNBC) patients of European ancestry treated with atezolizumab plus nab-paclitaxel (top) and placebo plus nab-paclitaxel (bottom) from IMpassion130. Patients were split into two groups on the basis of median split of the hypothyroidism PRS (hypoT) across all European ancestry IMpassion130 patients with germline genetic data. Censoring events are denoted by vertical dashes. Dashed horizontal and vertical lines designate the median survival time. Shaded regions provide the 95% confidence intervals. impas130 = IMpassion130. A = atezolizumab; NabP = Nab-paclitaxel.

Back to article page